Stockwinners Market Radar for February 27, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Grana y Montero notified of PEN79M civil compensation trust requirement in Peru - Grana y Montero and its subsidiary GyM S.A. have been notified of the Official Letter under which is reported that the Ministry of Justice and Human Rights has signed the Guarantee Trust Agreement that contributes to the payment of civil compensation, constituting a guarantee by Grana y Montero and GyM in favor of the Peruvian State under the terms and conditions of Law No. 30737 and its regulations. The Trust Agreement has been established considering a guarantee amount of S/. 79,116,443.66, as required by the Ministry of Justice and Human Rights to Grana y Montero S.A.A. and GyM S.A. The guarantee amount of the Trust will contribute to the potential civil compensation determined by the competent authorities under the provisions of the aforementioned Law in the event that, as a result of the investigations and legal proceedings in progress, former officers of Grana y Montero S.A.A. or former officers of GyM S.A. are declared responsible in acts of corruption admitted by Odebrecht in the South Interoceanic Road Corridor Peru - Brazil Project.

19:14 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: RubinconProject (RUBI) up 15.4%... California Resources (CRC) up 13.5%... Carvana (CVNA) up 9.9%... Collegium Pharma (COLL) up 9.3%... Hostess Brand (TWNK) up 8.8%... Qurate Retail (QRTEA) down 8.3%... Hilton Grand Vacations (HGV) up 8.1%... Monster Beverage (MNST) up 6.4%... Solaris Oilfield (SOI) up 6.2%... RegenxBio (RGNX) up 5.9%... Tutor Perini (TPC) up 5.6%... Ansys (ANSS) up 4.1%... FibroGen (FGEN) up 4.0%... Bilibili (BILI) up 3.9%... Universal Health (UHS) up 2.5%... Acceleron Pharma (XLRN) up 2.4%... Medallion Financial (MFIN) up 2.3%. ALSO HIGHER: T2 Biosystems (TTOO) up 30.3% after being granted "Breakthrough Device" designation for T2Resistance panel... Wabco (WBC) up 5.2% after confirming being approached by ZF Friedrichshafen and engagement in talks... Karyopharm Therapeutics (KPTI) up 3.4% after Point72 disclosed passive stake... DOWN AFTER EARNINGS: Box Inc (BOX) down 24.2%... Teladoc Health (TDOC) down 15.9%... Fitbit (FIT) down 14.1%... Boingo Wireless (WIFI) down 12.8%... HP Inc (HPQ) down 12.6%... Booking Holdings (BKNG) down 9.5%... Orbcomm (ORBC) down 8.8%... PRA Health (PRAH) down 6.9%... Elastic (ESTC) down 6.6%... Square (SQ) down 6.3%... Alteryx (AYX) down 6.3%... L Brands (LB) down 6.0%... Perrigo (PRGO) down 5.0%... Wingstop (WING) down 4.0%... Opko Health (OPK) down 4.0%... Ladder Capital (LADR) down 3.8%... Amedisys (AMED) down 3.4%.. Stoneridge (SRI) down 2.5%... Sarepta Therapeutics (SRPT) down 1.8%. ALSO LOWER: Syneos Health (SYNH) down 27.4% after delaying Q4 earnings release to review internal reporting controls... Applied Optoelectronics (AAOI) down 8.3% after convertible debt offering. Movers as of 18:30ET.

19:01 EDT Celsius Holdings agrees to establish China royalty license agreement - Celsius Holdings announced that they have executed a definitive agreement to establish a royalty license and repayment of investment agreement with Qifeng Food Technology Co., Ltd., creating a risk-mitigated method of capturing market share in China. Under the agreement, Qifeng Food will be granted the exclusive license rights to manufacture, market and commercialize Celsius Branded Products in China. Qifeng Food will provide a return of a fixed $6.9 million as a license fee covering the first five years, then transitioning to a volume-based royalty fee. In addition, Qifeng Food will repay all capital Celsius has invested into the China market to date, over a five-year loan term.

18:48 EDT Syneos Health delays Q4 earnings, to review internal financial controls - Syneos Health announced that it has delayed its previously announced earnings release and conference call to allow additional time to complete its Form 10-K for the year ended December 31, 2018. The company has filed a Form 12b-25, Notification of Late Filing, with the SEC and currently expects to file its Form 10-K within the 15-day extension period. The company has determined that additional time is needed for management to conduct a review of the Company's internal control over financial reporting in conjunction with the finalization of the Company's Form 10-K. On February 21, 2019, the company received notification from the SEC that it has commenced an investigation into the company's revenue accounting policies, internal controls and related matters, and the SEC has requested that the company retain certain documents for the periods beginning with January 1, 2017. The company is fully cooperating with the SEC.

18:38 EDT SunTrust exec Chancy sells 10,000 common shares - In a regulatory filing, SunTrust Banks executive Mark A. Chancy disclosed the sale of 10,000 common shares of the company at a price of $65.38 per share.

18:21 EDT GW Pharmaceuticals CEO: 'Epidiolex is different from other CBD options' - In an interview on CNBC's Mad Money, GW Pharmaceuticals CEO Justin Gover said: "We do real science and produce medicines with safety and efficacy... We're only reporting two months of sales, so some caution is warranted... Epidiolex is different from other CBD options... We're at the beginning of the journey with Epidiolex and looking at other uses for it... Epidiolex is not marijuana, it is CBD approved by the FDA."

17:58 EDT Wyndham Hotels & Resorts raises quarterly dividend to 29c from 25c per share - Payable March 29 to shareholders of record as of March 15.

17:48 EDT Silgan Holdings raises dividend 10% y-o-y to 11c per share - Silgan Holdings declared an 11c per share quarterly cash dividend on its common stock, payable on March 29 to the holders of record of the common stock on March 18, a 10% increase from last year.

17:43 EDT First Horizon receives SBA designation - First Horizon National has received Preferred Lender Program status by the Small Business Administration for lending through its banking subsidiaries, Capital Bank and First Tennessee Bank. "We are excited about growing to meet the needs of small business owners, who drive our nation's economy," said Adrienne Sipe, First Horizon's director of government guaranteed lending. "One of our goals is to be easy to do business with and our experienced staff and specialized technology help small business owners navigate the process as easily and efficiently as possible."

17:41 EDT iCAD enters exclusive relationship with researchers at Karolinska Institutet - iCAD announced their intent to enter into an exclusive relationship with two leading researchers at The Karolinska Institutet in Stockholm, Sweden, one of the world's foremost medical research universities, to develop an artificial intelligence based solution that will identify a women's individual risk of developing breast cancer. This partnership builds on an existing research agreement whereby researchers at the Karolinska Institutet developed a breast cancer risk prediction model using information identified in mammography images provided by iCAD's AI cancer detection and density assessment solutions. Promising early results based on mammography images from over 70,000 Swedish women enrolled in The Karolinska Mammography Project for Risk Prediction of Breast Cancer study were published in Breast Cancer Research in 2017. These data indicated that the model developed enabled early identification of women who were at a high-risk for breast cancer and it was determined that additional examinations were warranted. Since this publication, these results have been improved upon through the use of iCAD's latest ProFound AI algorithm. Among other things, the model now takes asymmetry of mammographic features and masking of tumors into consideration.

17:33 EDT HP Inc. says supplies revenue was weaker than expected, disappointing - Says price activity from consumers is an economic pressure. Says taking action to lower supply inventory. Says has work to do to manage current supply constraints. Says demand for products still remains strong. Says grew hardware revenue. Says expects currency headwind. Says needs to expand go to market initiatives. Says needs to diversify product pool. Comments taken from Q1 earnings conference call.

17:26 EDT WSFS Financial receives all required approvals to acquire Beneficial Bancorp - WSFS Financial Corporation (WSFS), the parent company of WSFS Bank, has received all required approvals to acquire Beneficial Bancorp (BNCL), and to merge its primary subsidiary, Beneficial Bank, into WSFS Bank. The Federal Reserve approved WSFS' acquisition of Beneficial, which is the final required regulatory approval for the proposed combination. With overwhelming approvals from WSFS and Beneficial shareholders, and regulatory approvals from the Federal Reserve and WSFS Bank's primarily regulator, the Office of the Comptroller of the Currency, WSFS expects to close the transaction on Friday, March 1.

17:11 EDT General Electric awarded $366.21M Navy contract for T-64 engine repair - General Electric has been awarded a $366.21M five-year, firm-fixed-price requirements, long-term contract for the repair of 18 different head-of-family part numbers in support of the T-64 engine. Work will be performed in Cherry Point, North Carolina, and work is expected to be completed by February 2024. Working capital funds will be obligated as individual task orders are issued and funds will not expire at the end of the current fiscal year. One company was solicited for this sole-source, non-competitive requirement in accordance with Federal Acquisition Regulation, with one offer received. Naval Supply Systems Command Weapon Systems Support is the contracting activity.

17:10 EDT Syneos Health trading halted, news pending

17:08 EDT Molecular Templates to present four abstracts on pipeline data at AACR - Molecular Templates announced that new data on its pipeline programs and technology platform will be presented in four posters at the American Association of Cancer Research, or AACR, annual meeting. Preclinical data on TAK-169, the company's CD38-targeted ETB, will be presented for the first time at the AACR meeting. This molecule is the most potent ETB that Molecular Templates has developed against any target to date. Importantly, in preclinical models, TAK-169 is active in the presence of daratumumab and active against daratumumab resistant cells. Molecular Templates will present on its CD38-targeted ETB, TAK-169. Although CD38 is a poorly internalizing receptor, TAK-169 is able to efficiently internalize and directly kill CD38-expressing cells. This novel mechanism of action may be relevant in patients who have progressed after or are unlikely to respond to CD38-targeted antibody therapy. TAK-169 has demonstrated potent cytotoxicity across a range of myeloma cell lines with a range of CD38 expression in vitro as well as in patient-derived samples including those with previous exposure to daratumumab. Furthermore, TAK-169 retains activity in the presence of excess approved, CD38 targeted therapeutic daratumumab. In xenograft models, complete regressions were observed using both a once-weekly and bi-weekly schedule of TAK-169. Tolerability studies in non-human primates demonstrate that repeat administration is tolerated at doses that are expected to be efficacious. TAK-169 is expected to enter the clinic in 2019. MT-3724 is a CD20-targeted ETB that has demonstrated single agent anti-tumor activity in heavily pre-treated relapsed/refractory Non-Hodgkin's lymphoma, or NHL, patients in a Phase I clinical study. The combination of MT-3724 with chemotherapeutic agents or an immunomodulatory agent all demonstrated additive or synergistic cytotoxicity of NHL cell lines. Additional clinical studies to evaluate MT-3724 as single agent and in combination with gemcitabine and oxaliplatin or lenalidomide are underway and expected to generate data in 2019. Molecular Templates has developed PD-L1-targeting ETBs as an approach to directly target tumor cells and overcome resistance mechanisms against PD-1 and PD-L1 antibodies. The cytotoxicity delivered by PD-L1-specific ETBs is engineered to be independent of a requirement for tumor infiltrating lymphocytes, high tumor mutational burden, or modulatory effects of the tumor microenvironment. Further, the activity is not dependent on blockade of the PD-1/PD-L1 checkpoint axis. Thus, PD-L1-targeting ETBs represent a distinct class of therapeutics with direct cell-kill mechanism of action and ability for activity in patients who have progressed on current standard of care or checkpoint therapy. In this presentation, the company highlights the efficacy and safety profile of MT-6020, a human and cynomolgus cross-reactive, PD-L1 targeted, ETB. MT-6020 binds to cell lines expressing non-human primate PD-L1 and elicits cytotoxic responses comparable to those observed on human tumor target cells. Molecular Templates' PD-L1 ETB, MT-6035, is built upon the MT-6020 scaffold and can also deliver a viral peptide for cell surface presentation and targeting by a specific antiviral CTL population for a second and complementary mechanism for tumor cell destruction, referred to as antigen seeding. MT-6020 and MT-6035 represent a novel approach to targeting and destroying tumors expressing PD-L1 that is unlikely to be inhibited by resistance mechanisms to current checkpoint inhibitors, is well tolerated in relevant toxicity models, and has the capacity for activity in indications where standard of care has failed. Molecular Templates expects to initiate clinical development of the PD-L1-targeted-ETB in 2H19. To further expand the therapeutic benefit of its ETB platform, Molecular Templates is characterizing ETBs that are targeted through multiple binding domains. Bispecific ETBs that target two epitopes on the same receptor, or two distinct cell surface molecules both expressed on cancer cells, may allow for enhanced activity profiles. These possibilities include: activity in the presence of a competitive binding protein sustained activity when one target molecule is shed or downregulated, synergistic binding events to increase overall potency, and increased specificity towards cancer over normal tissue. Bispecific ETBs have been generated to engage a variety of target combinations, relevant to both solid and hematologic cancer treatment. MTEM is exploring therapeutically relevant target combinations to facilitate the development of a bispecific clinical lead. By pairing the biology and potency of ETB-mediated killing with the expanded targeting possibilities afforded by bispecific molecules, Molecular Templates aims to develop a new class of therapeutics to benefit cancer patients.

17:04 EDT Air Transport Services sees FY19 adjusted EBITDA over $445M vs. $312.1M in FY18 - Air Transport Services currently projects Adjusted EBITDA for 2019 will exceed $445 million, reflecting a full year of contributions from Omni Air and from the freighter aircraft deployed during 2018. Most of the additional cargo aircraft deployments this year will be in the second half. As a result, a greater portion of that growth will occur later in the year. We also expect about $1.5 million in costs to ready crews for the additional 767s we will operate for Amazon. Air Transport Services projects that 2019 capital expenditures will total about $400Min 2019 vs. $292.9M last year, principally to purchase and modify Boeing 767 aircraft for freighter deployments in 2019 and 2020.

16:55 EDT Point72 Asset Management reports 5.8% passive stake in Karyopharm - Point72 Asset Management disclosed a 5.8% stake in Karyopharm , which represents over 3.5M shares. The filing does not allow for activism.

16:51 EDT Box slips 23.8% after providing downbeat FY, Q1 guidance

16:47 EDT Jounce Therapeutics to present ICONIC trial, JTX-8064 data at AACR - Jounce Therapeutics announced that data from its Phase 1/2 ICONIC trial, an open label trial evaluating JTX-2011 monotherapy and in combination with nivolumab, will be the subject of two poster presentations at the upcoming American Association for Cancer Research, or AACR, meeting. In addition, Jounce Therapeutics will present a poster that will describe the preclinical evaluation of JTX-8064, a highly specific monoclonal antibody that aims to reprogram human macrophages from an immune suppressive to immune active state by inhibiting the cell surface receptor LILRB2.

16:45 EDT Translate Bio provides updates on CF andOrnithine Transcarbamylase programs - Translate Bio provided an update on its lead clinical candidate, MRT5005, currently in development for the treatment of cystic fibrosis, and on its second product candidate, MRT5201, in development for the treatment of ornithine transcarbamylase deficiency.The initiation of the multiple-dose portion of the Phase 1/2 clinical trial of MRT5005 is an important milestone as it represents the first time that multiple doses of an mRNA therapeutic have been given to patients for the treatment of a genetic disease," said Ronald Renaud, chief executive officer, Translate Bio. "We look forward to expanding our knowledge of the safety profile of MRT5005 with multiple doses and believe that this progress underscores its potential to make an impact in the treatment of patients with cystic fibrosis."

16:44 EDT Wabco confirms approached by ZF Friedrichshafen AG, is engaged in talks - While it is the long-standing policy of Wabco Holdings not to comment on rumors in the marketplace or media reports, in response to market speculation and noting recent appreciation in its stock price, the company confirmed that it has been approached by ZF Friedrichshafen AG and has engaged in preliminary discussions concerning a potential transaction. There can be no assurance that any agreement will be reached with respect to a transaction or that a transaction will be consummated. The company further stated that it does not intend to make any additional comments on this matter unless and until it deems further disclosure is required.

16:42 EDT Darling Ingredients reports Q4 adjusted EBITDA $108.9M

16:39 EDT Syros Pharmaceuticals to present preclinical data on CDK7 inhibitors at AACR - Syros Pharmaceuticals announced that it will present new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 clinical trial focused on ovarian and breast cancers, and on SY-5609, its selective oral CDK7 inhibitor that the company has named as its next development candidate, at the American Association for Cancer Research Annual Meeting taking place March 29-April 3 in Atlanta. The presentation on SY-1365 will highlight data showing that alterations in the RB pathway are predictive of response to SY-1365 in patient-derived xenograft models of high-grade serous ovarian cancer, supporting exploration of RB alterations as potential biomarkers of response to SY-1365. The presentation on SY-5609 will describe in vitro and in vivo data on the selectivity, potency and anti-tumor activity of SY-5609 that supported its advancement into investigational new drug application ND-enabling preclinical studies.

16:37 EDT Mercury Systems receives $5.5M follow-on order - Mercury Systems announced that it received an additional $5.5 million in follow-on orders against its previously announced $152M 5 year sole-source basic ordering agreement to deliver advanced Digital RF Memory jammers to the U.S. Navy. The orders were received in Q2 and Q3 of FY19 are expected to be delivered over the next several quarters.

16:36 EDT CSS Industries announces 'successful' outcome of trade remedy cases - CSS Industries, Inc. announced the successful outcome of its trade remedy cases on plastic decorative ribbon from China. In a unanimous 5-0 vote, the U.S. International Trade Commission found that U.S. producers of plastic decorative ribbon have been materially injured by unfairly traded imports of plastic decorative ribbon from China. As a result, trade remedies, in the form of antidumping and countervailing duties, will be imposed on imports of plastic decorative ribbon from China at combined AD and CV duty rates ranging from 70.36% to 386.19%. These trade remedies are being implemented following investigations conducted by the ITC and the U.S. Department of Commerce in response to petitions filed by CSS' Berwick Offray LLC business in December 2017. Earlier in these investigations, the Commerce Department determined that Chinese producers and exporters were dumping plastic decorative ribbon into the United States at margins as high as 370.04%, and that Chinese producers were being unfairly subsidized at rates as high as 94.67%. Now that the ITC has made affirmative final determinations in these cases, AD and CV duty orders will be issued, imposing these duties. "We are excited by the outcome of these trade remedy cases," said Christopher J. Munyan, President and Chief Executive Officer of CSS. "We believe that vigorous enforcement of U.S. trade laws is essential to enabling U.S. companies like ours to compete on a level playing field when confronted with competition from dumped and unfairly subsidized imports from China. We are proud of our U.S. workforce and our Pennsylvania manufacturing facilities, which for decades have produced and reliably delivered to our customers high quality, on-trend and innovative plastic decorative ribbon products."

16:34 EDT Standex to sell CSG to Middleby in $105M deal - Standex International Corporation (SXI) announced that it has signed a definitive agreement to sell its Cooking Solutions Group, which is part of Standex's Food Service Equipment Group segment, to The Middleby Corporation (MIDD), a diversified food service equipment company. Upon the closing, Middleby will pay Standex a cash purchase price of $105 million, subject to post-closing adjustments. The closing of the transaction is subject to customary conditions, including regulatory approvals.

16:33 EDT Regions sees 2021 adjusted return on average tangible common equity of 18%-20% - Sees 2021 adjusted efficiency ratio less than 55%. Sees annual net charge-offs as a percentage of average loans of 40-65 bps from 2019-2021. Sees annual positive operating leverage from 2019-2021.

16:31 EDT Regions Financial outlines three-year growth strategy - Regions Financial presented the company's three-year strategic growth plan at an Investor Day in New York. Members of the company's management team reviewed investments Regions is making in talent, technology, and communities to make banking easier for customers, expand its reach to serve more consumers and businesses, and deliver attractive and sustainable returns to shareholders. The company announced it will pursue opportunistic hiring and de novo branch expansion in key growth markets including Atlanta, Houston, and Orlando. To support growth in these key markets as well as across the bank's service area, Regions expects to open new branches and hire corporate bankers, wealth management professionals, mortgage loan originators and other customer-facing associates to meet the needs of more individuals and businesses. Regions is funding these investments through continuous improvement initiatives that make banking easier for customers, simplify processes, and drive profitable, long-term growth. Regions also announced that it has allocated approximately $625 million this year, or 11 percent of 2018 revenue, for technology investments, with nearly half of that budget dedicated to new projects that will accelerate growth and improve the customer experience. Over the next three years, Regions will pilot voice banking capabilities and expand its use of AI for both customer-facing and back-office applications. Additionally, Regions is investing in data and analytics to provide more relevant financial advice to customers, improve the customer experience, and enhance credit risk management, as well as a variety of other internal processes across the company. In addition, Regions said it continues to reduce real estate square footage, the bank's second-largest expense category, through branch and back-office space consolidations, introduction of collaborative workspaces, hoteling, and expanding remote work options. The company is in the process of exiting 2.1 million square feet, resulting in a 15 percent reduction in total branch and non-branch space between 2017 and 2021. Regions is also delivering reductions in third-party spending through strategic sourcing and vendor selectivity and anticipates annual cumulative savings of approximately $60 million between 2018 and 2021.

16:30 EDT HP Inc. down 6.3% after reporting Q1 earnings, giving Q2, FY19 guidance

16:28 EDT California Resources sees FY19 capital program $300M-$385M - With current oil prices slightly above $60 per barrel Brent, CRC estimates its 2019 internally funded capital program will range from $300 million to $385 million, which may be adjusted during the course of the year depending on commodity prices. CRC is also in discussion to obtain additional investments from new and existing JVs that could increase the 2019 capital program by $100 to $150 million, to support a total capital budget of approximately $500 million. CRC's internally funded investments will be largely directed to quick payback projects, such as primary drilling and capital workovers, and low-risk projects including waterflood and steamflood investments that maintain base production.

16:27 EDT Menlo Therapeutics sees FY19 operating expenses $78M-$88M - Menlo expects that its current cash, cash equivalents and investments will enable the company to fund its anticipated operating expenses and capital expenditure requirements into Q4 of 2020. Menlo expects operating expenses for FY19 $78M-$88M, including stock-based compensation of $3M-$6M. The 2019 operating expenses will be primarily driven by ongoing development activities related to serlopitant.

16:25 EDT Wellington says it does not support Bristol-Myers' acquisition of Celgene - Wellington Management Company LLP recently informed the Board of Directors of Bristol-Myers Squibb (BMY) that it is not supportive of the company's proposed acquisition of Celgene Corporation (CELG). Wellington Management, which exercises investment discretion for clients with respect to approximately 8% of the company and, as of February 25, 2019, was the largest institutional holder of BMY's common stock, issued the following rationale for its decision: "While Wellington agrees that Bristol-Myers should be active in business development that secures differentiated science and broadens the future revenue base, Wellington does not believe that the Celgene transaction is an attractive path towards accomplishing this goal. Wellington's conclusion is based upon three tenets: 1) the transaction asks BMY shareholders to accept too much risk and the terms offer BMY shares to CELG shareholders at a price well below implied asset value; 2) execution success could be more difficult to achieve than depicted by Company management; and 3) alternative paths to create value for BMY shareholders could be more attractive."

16:24 EDT FBL Financial raises quarterly dividend 4.3% to 48c per share - The dividend is payable on March 29, 2019 to Class A and Class B common stockholders of record as of March 15, 2019.

16:23 EDT Acceleron expects BLA for luspatercept to be submitted in April - Acceleron (XLRN) said it and Celgene (CELG) plan to submit a Biologics License Application to the FDA for luspatercept in patients with anemia related lower-risk myelodysplastic syndromes and beta-thalassemia in April 2019. It added, Acceleron and Celgene remain on track to submit a Marketing Authorization Application to the European Medicines Agency for luspatercept in patients with anemia related to lower-risk MDS and beta-thalassemia in the first half of 2019...The ongoing Phase 2 trial of luspatercept in patients with MF has completed target enrollment, with preliminary results expected in the second half of 2019...Enrollment is ongoing in the COMMANDS Phase 3 trial in patients with first-line lower-risk MDS and the BEYOND Phase 2 trial in patients with non-transfusion-dependent beta-thalassemia, with preliminary results expected from the BEYOND trial in 2020."

16:22 EDT BioPharmX says NYSE grants compliance deadline extension - BioPharmX received a notice on February 25 from the NYSE American that granted the company an extension from February 27 to April 30 to regain compliance with certain NYSE American continued listing standards related to the low price per share of the company's common stock.

16:20 EDT U.S. FDA expands indication for Soliqua 100/33 - The U.S. FDA has approved the expanded use of Soliqua 100/33 100 Units/mL and 33 mcg/mL. Previously approved for use as an add-on to diet and exercise in adults with type 2 diabetes who are uncontrolled on long-acting insulin or lixisenatide, Soliqua 100/33 can now also be prescribed for patients uncontrolled on oral antidiabetic medicines. Sanofi will continue offering its savings program for Soliqua 100/33 which can limit out-of-pocket expenses sometimes to $0 for all commercially insured patients regardless of formulary status on an insurance plan or income level.

16:19 EDT Monster Beverage authorizes new $500M share repurchase program

16:18 EDT Middleby to acquire Standex Cooking Solutions Group for $100M - The Middleby Corporation (MIDD) announced that it has entered into a definitive agreement to acquire from Standex International Corporation (SXI) its Cooking Solutions Group, which consists of the well-known brands APW Wyott, Bakers Pride, BKI and Ultrafrye. In 2018, the Standex Cooking Solutions Group had revenues of approximately $100 million. The transaction completion is subject to customary closing conditions. Based in Allen, Texas, Standex Cooking Solutions Group has six locations, the Group headquarters, three manufacturing sites and two distribution centers. Products include combination and convection ovens, fryers, ranges, food merchandisers and warmers.

16:14 EDT MGM Resorts names title sponsor of 2019 MLB opening series in Tokyo - MGM Resorts will be the title sponsor of the 2019 MGM MLB Opening Series in Tokyo, Japan between the Oakland Athletics and Seattle Mariners. The AL West rivals open the 2019 Championship Season with a two-game set March 20-21 at the Tokyo Dome. As a new league partner, the 2019 MGM MLB Opening Series will be MGM Resorts' first major marketing activation around an MLB event.

16:12 EDT Square says continued to drive 'strong revenue growth at scale' - The company said to shareholders, "We continued to drive strong revenue growth at scale. In the fourth quarter of 2018, total net revenue grew 51% year over year and Adjusted Revenue grew 64% year over year. Excluding the acquisitions of Weebly and Zesty, which were acquired in the second quarter of 2018, total net revenue and Adjusted Revenue grew 47% and 53% year over year, respectively. Net loss was $28 million, compared to a net loss of $16 million in the fourth quarter of 2017. Excluding the loss of $17 million as a result of the mark-to-market valuation of our Eventbrite investment, net loss was $12 million. Adjusted EBITDA was $81 million in the fourth quarter of 2018, up 97% year over year, with margins improving compared to the fourth quarter of 2017."

16:11 EDT Square says outlook reflects 'both investment and growing profitability' - Square said in its letter to investors, "Given the significant market opportunity ahead of us, we will continue to be purposeful as we reinvest in our business to drive long-term growth. Our guidance for the full year of 2019 reflects both investment and growing profitability. As a reminder, the first quarter is typically our slowest in terms of sequential revenue growth due to seasonality. Additionally, our operating expense base will increase in the first quarter as we invest in growth opportunities."

16:08 EDT Synchronoss renews agreement to power BT Cloud - Synchronoss Technologies announced that it has renewed its agreement to power BT Cloud. BT Cloud is powered by the Synchronoss Personal Cloud platform and enhances BT's free online security offering, the most comprehensive of any major UK broadband provider. BT, a Synchronoss cloud services and storage partner since 2015, is the largest provider of consumer fixed-line voice and broadband services in the UK. BT Cloud gives customers secure backup and access to their photos, videos, contacts, files, music and messages from any device with an internet connection. This contract renewal signifies a deepening relationship between Synchronoss and BT. The BT Cloud service has since become a powerful differentiator for BT as the only major UK broadband provider to offer customers a secure backup service.

16:07 EDT Regenxbio sees cash, equivalents $330M-$350M as of December 31, 2019 - Based on its current operating plan, and excluding any commercial revenue from Novartis' (NVS) ZOLGENSMA, subject to approval by regulatory authorities, REGENXBIO (RGNX) reiterates that it expects its balance in cash, cash equivalents and marketable securities to be between $330M-$350M as of December 31, 2019, which will be used to support the continued development of its lead product candidate programs. Importantly, REGENXBIO anticipates adding commercial revenue from ZOLGENSMA to its existing base of partner revenue this year, pending approval by regulatory authorities.

16:04 EDT aTyr Pharma announces poster on ATYR1923 at Keystone Symposia - aTyr Pharma announced a poster presentation at the Keystone Symposia Conference. The poster describes a preclinical study to determine if aTyr Pharma's lead clinical candidate, ATYR1923, can influence myeloid cell migration. ATYR1923 was administered intravenously to C57BL/6 mice 24 hours prior to LPS challenge by airway administration to generate acute lung inflammation. Multi-color flow cytometry was used for immunophenotyping analysis and detection of NRP-2 levels on surfaces of various immune cell populations. In vitro, mouse bone-marrow derived macrophages, or BMDM, human THP-1 monocytic cells, and primary human dendritic cells (DCs) were used to confirm induction of NRP-2 cell surface expression following activation. This presentation highlights how ATYR1923 binds to both human and mouse NRP-2. NRP-2 is detected on the cell surface of myeloid cells both in vitro and in vivo. NRP-2 was induced following activation of TLR found on the cell surface, but not endosomal TLR ligands. ATYR1923 significantly decreased the CD11b+ population following LPS installation in the lung, which was ascribed to an inhibitory effect on neutrophil infiltration.

15:57 EDT WABCO trading resumes

15:49 EDT MongoDB CFO says 'really nothing changed' with Lyft - MongoDB (MDB) COO and CFO Michael Gordon said earlier during his presentation at the Morgan Stanley Technology, Media, and Telecom Conference that Lyft (LYFT) has been a customer of MLab, which MongoDB acquired, and that the ride sharing company has been "all-in" on Amazon's (AMZN) AWS since day one. He said, despite marketing around a database announcement from AWS that was "quite vague" and speculation in the marketplace, that he thinks "really nothing changed" with Lyft. He added "we didn't learn anything new yesterday" in terms of the AWS announcement regarding its partnership with Lyft. Shares of MongoDB were under pressure yesterday after Nomura Instinet analyst Christopher Eberle said he recently discovered that Lyft is "quite dissatisfied" with the company's performance and believes the ride-sharing service operator is in the process of a "massive database migration."

15:21 EDT WABCO trading halted, news pending

14:32 EDT Entegris comments on Merck KGaA's offer to acquire Versum - Entegris (ENTG) issued the following statement from Entegris CEO Bertrand Loy in response to Merck KGaA's (MKGAY) unsolicited offer to acquire Versum Materials (VSM): "The all-stock merger of equals of Entegris and Versum Materials will create a premier specialty materials company for the semiconductor and other high-tech industries and will be able to deliver meaningful value to Versum Materials and Entegris stockholders. We believe this combination is highly complementary and strategically compelling, providing stockholders of both companies with the opportunity to participate in the significant upside potential of the combined entity."

14:18 EDT Moody's downgrades Vale to Ba1; negative outlook - Moody's Investors Service has downgraded to Ba1 Vale S.A. senior unsecured ratings and the ratings on the debt issues of Vale Overseas Limited fully and unconditionally guaranteed by Vale. Moody's also downgrade to Ba2 the senior unsecured ratings of Vale Canada Ltd. The outlook for all ratings is negative. Vale is down over 1% to $12.39 per share in afternoon trading.

13:48 EDT Littelfuse director Nathan Zommer sells over $250K in company shares - Littelfuse director Nathan Zommer disclosed in a filing that he had sold 1,300 shares of company stock at an average price of $194.14 per share on February 25. The total transaction value was $252,382.

13:26 EDT GTY Technology Holdings budgeting solution awarded $6M in new contracts - GTY Technology Holdings announced over $6M in newly awarded contracts to one of its budgeting solutions, Sherpa Government Solutions. The contracts were awarded by the City of Phoenix, AZ, Riverside County, CA, and Yolo County, CA. The contract with the City of Phoenix represents one of the largest bookings in the history of GTY's six business units, the company said.

12:31 EDT City Holding board approves plan to buy back up to 1M common shares - City Holding Company announced that the board authorized the company to buy back up to 1,000,000 of its common shares, or approximately 6% of outstanding shares, in open market transactions at prices that are accretive to the earnings per share of continuing shareholders. Management may commence or suspend purchases at any time or from time-to-time based on market and business conditions and without prior notice. No time limit has been placed on the duration of the share repurchase program. As part of its authorization, the company rescinded the previous share repurchase plan approved in September 2014. Through February 27, 2019, the Company repurchased 888,243 shares under the September 2014 plan. City Holding Company is the parent company of City National Bank of West Virginia.

12:01 EDT e.l.f. Beauty falls -21.7% - e.l.f. Beauty is down -21.7%, or -$2.06 to $7.42.

12:00 EDT Dril-Quip rises 16.7% - Dril-Quip is up 16.7%, or $6.17 to $43.03.

12:00 EDT Sea Limited rises 26.0% - Sea Limited is up 26.0%, or $4.22 to $20.42.

11:52 EDT Enersis Americas trading resumes

11:45 EDT IAG board recommends special dividend of EUR 0.35 per share - The Board of International Consolidated Airlines Group S.A decided to recommend to shareholders a final dividend of EUR 0.165 per share in respect of 2018. It has also decided to recommend to shareholders a special dividend of EUR 0.35 per share. Subject to shareholder approval at IAG's annual meeting, the final and special dividends will be paid on July 8 to shareholders on the register on July 5.

11:26 EDT Versum Materials trading resumes

11:16 EDT Versum responds to unsolicited $48 per share takeover offer from Merck KGaA - Versum Materials (VSM) issued the following statement in response to the unsolicited proposal by Merck KGaA (MKGAY) to acquire Versum for $48.00 per share in cash. "Versum continues to believe in the strategic and financial rationale of the proposed merger of equals with Entegris (ENTG). Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, Versum's board of directors will thoroughly review the Merck proposal." Lazard is serving as exclusive financial advisor to Versum Materials and Simpson Thacher & Bartlett LLP is serving as legal counsel.

11:08 EDT Versum Materials trading halted, news pending

10:30 EDT Harley-Davidson raises Q1 dividend by 1.4% to 37.5c per share - Harley-Davidson's board has approved a cash dividend of 37.5c per share for 1Q19, an increase of 1.4% compared to the 1Q18 dividend of 37c per share. The dividend is payable March 29, to the shareholders of record as of March 14.

10:13 EDT Reuters expands sports offering with content partnerships. - Reuters announced it is further expanding its sports content offering to Reuters News Agency customers through multimedia partnerships with the Players' Tribune, AFLO, Panoramic, Sporting Images and MB Media. These new partnerships add to a growing roster of sports partners on Reuters Connect at the same time that Reuters own sports coverage is expanding, making Reuters Connect an essential tool for sports desks. Through these new partnerships, Reuters News Agency customers will have access to candid athlete video interviews via the Player's Tribune; more than 50,000 curated archival images from Sporting Images; more than 6,000 player headshots through MB Media; and regional photo coverage from Japan via AFLO and France via Panoramic.

10:07 EDT Jensyn Acquisition announces agreement to combine with Peck Electric - Jensyn Acquisition Corp., a company formed for the purpose of entering into a merger, share exchange, asset acquisition or other similar business combination with one or more businesses or entities, announced that it has signed a definitive agreement to enter into a business combination with Peck Electric Co., which it calls "the largest commercial solar Engineering - Procurement - Contracting company in the Northeast and ranked 60th in the USA by Solar Power World." At the closing of the business combination, the stockholders of Peck Electric Co. will exchange their shares in Peck Electric Co. for 3,234,501 shares of Jensyn common stock representing approximately 59% of Jensyn's outstanding shares after giving effect to the business combination. In addition, the stockholders of Peck Electric Co. will be entitled to an additional 898,473 shares of Jensyn common stock if Jensyn's adjusted EBITDA is $5M or more for the twelve-month period following the closing of the business combination or the closing price of Jensyn's common stock is $12.00 or more at any time during such twelve-month period. Upon the closing of the business combination, Peck Electric Co. will become a wholly-owned subsidiary of the company that will be named "The Peck Company, Inc." whose common stock is expected to be listed on The Nasdaq Capital Market under the symbol "PECK." The closing of the business combination is subject to a number of conditions, including the approval of Jensyn's Board of Directors and stockholders, and Jensyn's reasonable satisfaction with the results of its due diligence investigation of Peck.

10:03 EDT U.S. Navy selects BAE Systems to compete for future cyber engineering orders - The U.S. Navy has selected BAE Systems to compete for future cyber engineering task orders awarded under a seven and a half-year, indefinite delivery/indefinite quantity contract. The contract vehicle is intended to be used by naval, joint and national agencies seeking lifecycle service support for command, control, communications, computers, and combat systems. Additional task orders may be awarded to enhance the capabilities and security of various signals intelligence, imagery intelligence, electronic warfare, surveillance, and reconnaissance systems. The award may also be used to develop, test, produce, and field next-generation autonomous and unmanned missions systems. BAE Systems is one of ten companies selected to compete for future task orders awarded under the IDIQ, which is being managed by Space and Naval Warfare Systems Center Atlantic. The ceiling value for all future task orders awarded under the contract is $898M.

10:00 EDT Dean Foods falls -15.8% - Dean Foods is down -15.8%, or -72c to $3.83.

10:00 EDT Dycom falls -27.1% - Dycom is down -27.1%, or -$16.79 to $45.21.

10:00 EDT Versum Materials rises 17.4% - Versum Materials is up 17.4%, or $7.19 to $48.59.

10:00 EDT Sea Limited rises 22.5% - Sea Limited is up 22.5%, or $3.65 to $19.85.

09:47 EDT Dean Foods falls -15.4% - Dean Foods is down -15.4%, or -70c to $3.85.

09:47 EDT e.l.f. Beauty falls -26.7% - e.l.f. Beauty is down -26.7%, or -$2.54 to $6.95.

09:47 EDT Versum Materials rises 17.7% - Versum Materials is up 17.7%, or $7.33 to $48.73.

09:44 EDT GE Capital 'not a zero,' but a 'substantial negative,' JPMorgan's Tusa says - JPMorgan analyst Stephen Tusa is speaking on CNBC.

09:41 EDT JPMorgan's Tusa says 'the math is the math' on General Electric - JPMorgan analyst Stephen Tusa is speaking on CNBC.

09:39 EDT JPMorgan's Tusa says rally in GE shares 'has gone way too far' - JPMorgan analyst Stephen Tusa is speaking on CNBC.

09:29 EDT Enersis Americas trading halted, news pending

09:13 EDT Mattel and MGM to develop live action motion picture based on View-Master - Mattel and Metro Goldwyn Mayer Pictures have partnered to develop a live action motion picture based on Mattel's toy line View-Master. Mattel updated the version of the classic View-Master with View-Master VR. Mattel Films and MGM will co-produce the film. This is the second recent collaboration between Mattel Films and MGM, following the companies' recent announcement to create a feature film based on the American Girl brand.

09:13 EDT ResMed subsidiary enters eMAR agreement with PharMerica - MatrixCare, a wholly owned subsidiary of ResMed, announced that it has entered into a national pharmacy integration and electronic medication administration record, or eMAR, agreement with PharMerica, a long-term care pharmacy service for senior living communities, public health organizations and post-acute care facilities. The agreement covers NCPDP Bidirectional ePrescribing with all MatrixCare customer facilities as well as pharmacy-centric order entry, or PCOE, integration with MatrixCare's CareAssist platform, which combines eMAR and point-of-care functionality to help streamline workflows and documentation for frontline caregivers in skilled nursing, assisted living and senior living communities. This agreement allows MatrixCare to communicate with PharMerica's proprietary AS400 software in multiple configurations.

09:07 EDT SS&C signs multi-year agreement with Federal Home Loan Bank of Dallas - SS&C announced that Federal Home Loan Bank of Dallas has signed a multi-year agreement to use SS&C Primatics' EVOLV platform. EVOLV will allow FHLB Dallas to automate mortgage loan accounting processes and facilitate reserving under the Current Expected Credit Loss accounting standard within a controlled environment.

09:06 EDT Nielsen's TV ratings LPM services renewed by Viamedia - Nielsen and Viamedia, a cross-media advertising company, have reached a multi-year renewal agreement for Nielsen TV ratings LPM service for the greater Philadelphia market including Nielsen Scarborough national custom qualitative service as well as Nielsen Rhiza services in 75 LPM, Set Meter and Return Path Data markets. The agreement includes a range of audience measurement and analytical services.

09:05 EDT Best Buy says it made significant progress driving 2020 strategy - Says will be actively participating in the rise of 5G. Says digital health space an opportunity. Says SG&A dollars will increase in FY19. Says will continue to invest in development of customer support. Says gaming is cyclical business. Says consumer confidence combined with execution and acceleration of strategy were responsible for better than expected results. Comments taken from Q4 earnings conference call.

09:03 EDT Huntington Ingalls buys Fulcrum IT Services for $193M - Huntington Ingalls has bought Fulcrum IT Services, a portfolio company of Boyne Capital and Grindstone Partners, private equity firms focused on small and mid-sized companies, for $193M. Boyne and Grindstone acquired Fulcrum in 2010 in partnership with management. Headquartered in Centreville, Virginia, Fulcrum is an IT and government consulting company that provides pivotal solutions and services primarily for federal customers in the defense, intelligence, education and healthcare sectors.

08:55 EDT Barnes & Noble Education, Macmillan Learning announce expanded partnership - Barnes & Noble Education and Macmillan Learning announced an expanded partnership to ensure more students have immediate and affordable access to their course materials. Through the companies' new agreement, Macmillan Learning's digital content, courseware, and eBooks will be made available nationwide through inclusive access models offered on campuses served by BNED through its Barnes & Noble College and MBS Textbook Exchange subsidiaries.

08:53 EDT State Street appoints Lou Maiuri as COO - State Street announced that its board of directors has appointed Lou Maiuri, previously head of State Street's Global Markets and Exchange businesses, to the role of COO. In this capacity, he will have overarching responsibility for State Street's IT, Global Delivery, Global Exchange, Charles River Development and Product teams. Maiuri will continue to serve on State Street's Management Committee and report to President and CEO Ron O'Hanley.

08:47 EDT Sky Solar: Hudson withdraws Cayman Islands, Hong Kong statutory demands - Sky Solar Holdings announced that Hudson withdrew the Statutory Demands it previously served on the company and a certain subsidiary of the company in the Cayman Islands and Hong Kong, respectively. The company intends to vigorously defend against Hudson's other actions and proceedings in order to minimize interruptions to its business and operations. The company is committed to preserving and maximizing shareholder value.

08:44 EDT Campbell says Snyder-Lance's value capture slightly ahead of expectations YTD

08:39 EDT Best Buy increases dividend 11% to 50c per share - Best Buy announced its board approved an 11% increase in the regular quarterly dividend to 50c per share, effective immediately. This is the sixth consecutive year the company has increased the dividend. The regular quarterly dividend will be payable on April 10 to shareholders of record as of the close of business on March 20.

08:35 EDT InflaRx announces Health Canada approval to initiate Phase 2a IXF-1 trial - InflaRx announced the approval of a clinical trial application by Health Canada for a phase 2a clinical trial evaluating the company's lead product candidate, IFX-1, in Pyoderma Gangraenosum. This is the third autoimmune disease for which InflaRx is developing IFX-1. Pyoderma Gangraenosum, or PG, is a rare and debilitating neutrophilic-driven, autoinflammatory disease, characterized by an acute, destructive ulcerating process of the skin, primarily occurring on the legs. The exact prevalence of PG is not yet known, but it is estimated that up to 50,000 patients in the US and Europe are affected by this disease.

08:32 EDT TJX board authorizes additional $1.5B stock repurchase program - The Company announced its plan to repurchase approximately $1.75B to $2.25B of TJX stock during the fiscal year ending February 1, 2020. With $1.7B remaining at Fiscal 2019 year end under the Company's stock repurchase programs, the Company's Board of Directors approved a new stock repurchase program that authorizes the repurchase of up to an additional $1.5B of TJX common stock from time to time. The new authorization represents approximately 2% of the Company's outstanding shares at current prices. The new stock repurchase program marks the 20th program approved by the Board since 1997. Over this period, the Company has spent approximately $22.1B on the repurchase of TJX stock. During the fourth quarter, the Company spent a total of $855M to repurchase TJX stock, retiring 17.8 million shares. In Fiscal 2019, the Company spent a total of $2.5B to repurchase TJX stock, retiring 51.8 million shares. Under the Company's repurchase plans, share repurchases may be made from time to time in market or private transactions and may include derivative transactions. The repurchase program announced today has no time limit and may be suspended or discontinued at any time.

08:30 EDT TJX intends to raise quarterly dividend 18% to 23c per share - With the Company's continued strong cash flow, TJX intends to increase the regular quarterly dividend on its common stock to be declared in April 2019 and payable in June 2019 to 23c per share, subject to the approval of the Company's Board of Directors. This would represent an 18% increase in the current per share dividend and mark the 23rd consecutive year that the Company has raised the dividend. Over this period of time, the Company's dividend has grown at a compound annual rate of 22%.

08:25 EDT Sarepta says 90% reduction in CK in first 3-patient cohort 'very encouraging'

08:24 EDT Tesla CEO Elon Musk teases 'some Tesla news" on Thursday - Tesla CEO Elon Musk said via Twitter: "Some Tesla news. California. Thursday 2pm." Reference Link

08:21 EDT Sarepta executive calls gene therapy results 'remarkable but preliminary' - Sarepta Therapeutics is presenting Limb-Girdle muscular dystrophy type 2E data on a conference call.

08:16 EDT Uniti Group comments on Windstream reorganization under Chapter 11 - Uniti Group (UNIT) commented on the commencement of voluntary reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code by Windstream (WIN) and all of its subsidiaries in the U.S. Bankruptcy Court for the Southern District of New York. Windstream is Uniti's largest customer and tenant under a master lease agreement. In a press release issued February 25, Windstream indicated it has secured $1B of debtor-in-possession financing, expects to continue operating in the normal course of business and intends to pay vendors in full for all goods received and services provided to Windstream after the filing date. Kenny Gunderman, president and CEO of Uniti, commented, "We continue to closely monitor Windstream's situation, and believe it will successfully navigate through the reorganization process. We were pleased to see Windstream state its intent to continue operations in the ordinary course and pay in full its service providers. We are also encouraged by the Federal Communications Commission's ("FCC") recent statement regarding the importance of Windstream's continued service to its customers, and the FCC's focus on the importance that federal funds provided to Windstream are put to their appropriate use. We believe access by Windstream to Uniti's network remains critical to Windstream's operations and ability to serve those customers."

08:11 EDT WPP names Jacqui Canney global chief people officer - WPP announced the appointment of Jacqui Canney as global chief people officer, effective June 1, 2019. In this role, Canney will be responsible for WPP's global talent organisation, making WPP the destination for the industry's top talent and leading all aspects of people strategy, rewards, talent management, recruiting, and leadership development and learning. Reporting to WPP CEO Mark Read, she will create an integrated talent team that will work with leaders throughout the company to help build a new culture that empowers people to do their best work. As EVP, chief people officer at Walmart (WMT). she is responsible for attracting, retaining and developing talent for one of the world's largest private employers. Canney succeeds Mark Linaugh, who has decided to retire from the business and will stay on until the summer to ensure a smooth handover process.

08:07 EDT Eiger BioPharmaceuticals appoints Stephana Patton as General Counsel - Eiger BioPharmaceuticals appointed Stephana Patton as the company's General Counsel, Corporate Secretary, and Chief Compliance Officer. Patton was most recently General Counsel, Corporate Secretary, and Chief Compliance Officer at BioTime.

08:05 EDT Merck KGaA offers to acquire Versum Materials for $48 per share - Merck KGaA (MKGAY) has proposed to the board of directors of Versum Materials (VSM) that Merck should acquire all of the issued and outstanding common shares of Versum for $48 per share or an enterprise value of $5.9B in an all-cash transaction. This offer represents a substantial premium to the last undisturbed share price before the Versum/Entegris (ENTG) merger announcement of 51.7% and a 15.9% premium to Versum's closing price on February 26, 2019. Merck's Executive Board unanimously approved the proposal and is fully committed to pursuing the transaction. Merck is prepared to proceed immediately to due diligence and negotiations and to quickly agree to a merger agreement. The completion of the offer will be subject to customary closing conditions, including the receipt of necessary regulatory clearances. A Merck shareholder vote is not required.

08:03 EDT Merck KGaA offers to acquire Versum Materials for $48 per share

07:51 EDT Peabody Energy declares supplemental cash dividend of $1.85 per share - Peabody has declared a supplemental dividend of $1.85 per share, payable on March 20 to holders of record on March 12. The total amount of the supplemental dividend payment will be approximately $200M based on the current number of shares outstanding and will be funded through existing cash balances. In 2019, the company expects to allocate an amount equal to or greater than its free cash flow to shareholder returns. The supplemental dividend is in addition to the company's previously declared quarterly dividend of 13c per share, payable on March 6 to shareholders of record on Feb. 20. The company also has approximately $415M remaining under its current $1.5B authorization for share repurchases. Peabody's liquidity target remains $800M and stood at $1.32B at Dec. 31.

07:44 EDT Campbell Soup CEO says efforts to stabilize core business 'on track' - Mark Clouse, Campbell's President and CEO stated, "I am pleased that, for the second consecutive quarter, we delivered sales and earnings performance in line with our expectations, enabling us to reaffirm our full-year guidance for fiscal 2019. During the quarter, we continued to make progress against key strategic initiatives. Our efforts to stabilize our core business, integrate Snyder's-Lance, deliver our cost savings agenda and focus and optimize the portfolio are all on track. Over time, these actions will enable us to increase investments in our core businesses while significantly reducing debt and creating meaningful value for shareholders. While we have made steady progress, there is much more work to be done to fully unlock the potential of our business. Since joining the team and immersing myself in Campbell's business, I am confident in the plans in place to address our near-in challenges and opportunities, with the commitment to set a clear strategic roadmap for the future. I am excited by the opportunities to build upon the company's solid foundation of iconic brands, talented employees, engaged customers and loyal consumers. It is upon these strengths that we will continue to create a compelling plan that delivers profitable and sustainable growth, supported by a reenergized culture focused on accountability, performance and consumer-driven marketing and innovation."

07:38 EDT Axon receives order for 550 body cameras from Buffalo Police Department - Axon announced that Buffalo Police Department will deploy 550 Axon Body 2 cameras backed by the digital data management solution Axon Evidence. This order was received in Q4 and will ship in multiple phases. Other orders include Savannah Police Department for 542 Axon Body 2 cameras on a 5-year contract, San Mateo County Sheriff's Office for 537 Axon Body 2 cameras and 80 Axon Fleet 2 in-car video systems on a 5-year contract, and Santa Monica Police Department for 325 Axon Body 2 cameras, 35 Axon Flex 2 cameras and 65 Axon Fleet 2 in-car video systems on a 5-year contract.

07:34 EDT Sinclair Broadcast sees Q1 media revenue $667M-$673M

07:18 EDT MYOS partners with Kansas State University in impact study of Fortetropin - MYOS has signed an agreement with Kansas State University College of Veterinary Medicine to evaluate the impact of Fortetropin on quality of life and activity in geriatric dogs. This veterinary clinical study follows the announcement of positive results from a randomized, double-blind, placebo-controlled study that examined the impact of Fortetropin on recovery following tibial plateau leveling osteotomy surgery in dogs. 40 geriatric dogs that suffer from three of the following conditions will be recruited to participate in the study: weakness, weight loss, slowed or altered mobility, or exercise intolerance.

07:16 EDT Walmart, Affirm announce omnichannel partnership - Affirm announced a partnership with Walmart that will give shoppers the option of using Affirm to pay for their purchases over time at nearly 4,000 Supercenters nationwide. Walmart will begin to integrate Affirm as a payment option on Walmart.com over the coming weeks. Once approved, shoppers select a repayment term of 3, 6, or 12 monthly installments and are shown the exact repayment amount they'll owe each month, with interest displayed in simple dollars rather than as a hard-to-calculate interest rate. There are no hidden or late fees, so users will never pay a dollar more than they agree to. For in-store shoppers, they will receive a unique barcode that is scanned by a store associate at the register to complete a purchase.

07:14 EDT Medtronic announces FDA clearance for Accurian RF ablation platform - Medtronic announced U.S. Food and Drug Administration 510(k) clearance of the Accurian RF ablation platform, which conducts radio frequency ablation of nerve tissues. RF ablation is a minimally invasive procedure in which current produced by radio waves heats up a small area of nerve tissue to stop it from sending pain signals, thereby reducing pain. The Accurian system combines proprietary hardware and quad core processing with advanced software for power and temperature control resulting in consistent and predictable lesion formation. It also offers independent channel management and advanced smart features that may support procedural efficiency.

07:12 EDT Gevo announces long-term supply agreement with HCS Group - Gevo announced that HCS Group and Gevo have entered into a long-term, definitive, binding and bankable renewable isooctane purchase and sale agreement, dated February 21. HCS Group will be supplied exclusively for sales of Gevo's renewable isooctane into high-end applications ranging from high purity solvents to specialty fuels under its Haltermann Carless brand, excluding use of isooctane for on-road transportation fuels. Gevo's renewable isooctane is a low-carbon, drop-in blending component for gasoline and has the potential to reduce greenhouse gases by as much as 70%, well within the standards established by the EU Renewable Energy Directive. This long-term, binding purchase and sale agreement with HCS Group is an important step forward in Gevo's previously-announced strategy to build out Gevo's advanced biofuels production facility in Luverne, Minnesota to increase the production of renewable isobutanol and renewable jet fuel as well as isooctane. Pursuant to the terms of the agreement, Gevo will supply low-carbon, renewable isooctane to HCS Group over ten years if certain conditions are met, including the expansion of Gevo's isooctane production capabilities at its advanced biofuels production facility in Luverne.

07:09 EDT Idera Pharmaceuticals completes enrollment in Phase 2 ILLUMINATE-204 trial - Idera Pharmaceuticals announced completion of enrollment into the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered toll-like receptor 9, or TLR9, agonist, in combination with ipilimumab in patients with unresectable or metastatic melanoma following failure of PD-1 inhibitor treatment. Overall, 52 patients have been dosed in the trial which included two separate patient groups. The company completed the targeted enrollment of 40 patients in the primary enrollment population, constituting patients who are naive to prior ipilimumab treatment in the metastatic setting. This patient population mirrors the enrollment for the ILLUMINATE-301 phase 3 pivotal trial. The secondary exploratory enrollment population targeted up to 20 patients who had prior ipilimumab treatment in the metastatic setting. The ILLUMINATE-204 trial is a multi-center trial being conducted at 10 sites throughout the United States. The company is currently enrolling ILLUMINATE-301, a global, multi-center, randomized Phase 3 trial that compares effectiveness and safety between two treatment groups: tilsotolimod combined with ipilimumab versus ipilimumab given alone. This trial is being conducted at up to 100 centers with a target enrollment of 308 patients. Enrollment remains on track and is expected to be completed in Q4. The company also recently received notice from the FDA that the company can proceed to implement the ILLUMINATE-206 clinical trial under a new investigational new drug, or IND, application. The ILLUMINATE-206 trial will test the safety and effectiveness of tilsotolimod in combination with ipilimumab and nivolumab in treating patients with Squamous Cell Carcinoma of the Head and Neck and Microsatellite Stable Colorectal Cancer. The ILLUMINATE-206 trial is expected to initiate in Q2.

07:07 EDT Main Street announces regular monthly dividend increase - Main Street Capital is pleased to announce that its Board of Directors declared regular monthly cash dividends of 20c per share for each of April, May and June 2019. These monthly dividends total 60c per share for the second quarter of 2019 and represent a 5.3% increase from the regular monthly dividends paid for the second quarter of 2018 and a 2.6% increase from the regular monthly dividends declared for the first quarter of 2019. Since its October 2007 initial public offering, Main Street has periodically increased the amount of its regular monthly dividends paid per share and has never reduced its regular monthly dividend amount per share. Including all dividends declared to date, Main Street will have paid $25.42 per share in cumulative cash dividends since its October 2007 initial public offering at $15.00 per share.

07:04 EDT Chesapeake sees FY19 CapEx $2.3-$2.5B - 2019 Outlook... Transformational oil growth: Projected 2019 average daily oil production of approximately 116,000 to 122,000 bbls, an absolute increase of approximately 32% (or 50% adjusted for asset sales), driven by the acquisition of the WildHorse asset and organic growth from the PRB; oil mix projected to be approximately 26% by 2019 fourth quarter. Capital expenditure program discipline: Projected 2019 capital expenditures range from $2.3B-$2.5B, effectively flat compared to $2.366B in 2018. Lower costs lead to improved capital efficiency and enhanced competitiveness: Cash costs projected to decrease by approximately $200M, driven by lower gathering, processing and transportation expenses partially offset by slightly higher production and general and administrative expenses as a result of production and working interest mix; EBITDA generated per boe projected to increase by approximately 12%-15%, based on recent strip prices.

06:53 EDT Quest Diagnostics announces lab management partnership with South Carolina RMC - Quest Diagnostics and Regional Medical Center, or RMC, of Orangeburg, South Carolina, are teaming up to enhance the quality and value of diagnostic services for patients and their doctors through a new partnership agreement under which Quest will provide full laboratory management services. Under the agreement, Quest will provide management expertise, laboratory equipment, reference testing, supplies and procurement processes for RMC.

06:50 EDT Dean Foods suspends quarterly dividend

06:38 EDT Denbury Resources sees 2019 production 56K-60K BOE/d - 2019 capital budget, excluding acquisitions and capitalized interest, is $240M-$260M, a decrease of 20% to 25% from the company's 2018 capital spending level.

06:35 EDT Donnelley Financial Solutions sees FY19 adjusted EBITDA $145M-$155M - Sees FY19: CapEx $40M-$45M; free cash flow $40M-$45M; adjusted effective tax rate 29%-31%.

06:28 EDT Bayer completes rolling submission for darolutamide in the U.S. - Bayer announced the completion of the rolling submission of a New Drug Application for darolutamide to the U.S. Food and Drug Administration. The submission, which was initiated in December 2018, is based on data from the Phase III ARAMIS trial in men with non-metastatic castration-resistant prostate cancer showing a statistically significant improvement in metastasis-free survival for darolutamide plus androgen deprivation therapy. Darolutamide plus ADT has shown a favorable safety profile compared to placebo plus ADT. These data were recently presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco and published simultaneously in The New England Journal of Medicine. Bayer has been granted Fast Track designation by the U.S. Food and Drug Administration for darolutamide in men with nmCRPC. Bayer is also in discussions with other health authorities regarding a submission for darolutamide. The compound is being developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.

06:24 EDT Bayer faces lawsuits from approx. 11,200 plaintiffs in the U.S. over glyphosate - As of January 28, 2019, lawsuits from approximately 11,200 plaintiffs had been served in the United States in connection with the crop protection product glyphosate. "We disagree with the ruling by a court of first instance in the Johnson case and have therefore filed an appeal," the company said. Also in respect of further proceedings, seven of which are currently scheduled for this year, he added: "We have the science on our side and will continue to vigorously defend this important and safe herbicide for modern and sustainable farming."

06:18 EDT GCP Applied Technologies to conduct review of strategic alternatives - In a letter to shareholders, the company states: "The Board and management team are evaluating and exploring the best paths forward for delivering value for our shareholders. Our views are informed by our insights into the competitive landscape, as well as the challenges and opportunities the business is facing. We will evaluate all strategic, financial and operational alternatives, which may include the sale of GCP, a strategic business combination, the continued execution of our business plan or some combination of these, all with a view to maximizing value for our shareholders. Our review will be performed with the assistance of our independent financial advisor, Evercore. We look forward to input from our shareholders during this process. We intend to be thorough and diligent in evaluating the relative benefits of various alternatives and completing our review in a timely and orderly manner. We do not expect to make further public comments regarding these matters unless and until the Board has approved a specific course of action or otherwise determined that further disclosure is necessary or appropriate. This is just the beginning of the process - and there can be no assurance that this process will result in GCP completing any specific action or transaction. Whatever path we pursue, we will continue to focus on execution and the performance of our business. Today, we announced a restructuring plan that is focused on GCP's global supply chain strategy, processes and execution, including our manufacturing, purchasing, logistics, and warehousing operations. An independent expert consulting firm has been assisting us in this review of our supply chain. The plan also addresses our service delivery model primarily in North America to streamline our pursuit of combined admixture and VERIFI opportunities. This restructuring plan is the next step in our cost improvement effort to reduce GCP's complexity and create a more focused, efficient and effective organization. We began the cost improvement effort in 2017 with the sale of Darex and since then have restructured and repositioned our Specialty Construction Chemicals business by exiting low profit geographies to improve our earnings. Our 2019 plan is expected to deliver an additional approximately $25M in total annualized cost savings, bringing total expected annualized cost savings from our three restructuring programs to approximately $80 million in 2020. Furthermore, the company will continue to look for additional efficiencies and ways to improve our operational performance. On August 9, 2018, Starboard Value began accumulating a position in GCP and has recently informed us of its beneficial ownership of approximately 4.6% of GCP's outstanding shares as of February 26, 2019. Starboard has also provided notice to us that it intends to nominate five director candidates to stand for election at our 2019 Annual Meeting of Shareholders. We informed Starboard that our Nominating and Governance Committee will evaluate its nominees, along with our existing directors and other candidates identified by our independent search firm and other shareholders, as part of our Board's continuing refreshment process. We have also met with Starboard and will continue to have discussions with them as part of this refreshment process."

06:13 EDT Lowe's reports $1.6B pre-tax charges in Q4 - Lowe's Companies reported a net loss of $824M and diluted loss per share of ($1.03) for Q4, which included pre-tax charges of $1.6B. The $1.6B in pre-tax charges recognized in the fourth quarter included the following: $952M related to a non-cash goodwill impairment charge associated with the company's Canadian operations; $208M of charges, primarily lease obligations, related to the previously announced closing of all Orchard Supply Hardware locations; $150M of charges, primarily lease and severance obligations as well as accelerated depreciation and amortization, related to the previously announced closing of certain underperforming stores in the U.S. and Canada as well as other locations in Canada; $222M related to asset impairment charges associated with the previously announced exit of retail operations in Mexico; $32M of inventory write-down, severance obligations and other costs associated with the wind down of Iris Smart Home; and $13M in severance obligations associated with the elimination of the Project Specialists Interiors position.

06:11 EDT GCP Applied Technologies reports Q4 adjusted EBITDA down 11% to $42.8M

06:10 EDT HomeStreet signs LOI with Homebridge Financial Services - HomeStreet has announced that it has entered into a non-binding letter of intent for Homebridge Financial Services to potentially acquire the assets related to HomeStreet's stand-alone home loan centers and to hire HomeStreet's related mortgage personnel. HomeStreet had previously announced that it was exploring a potential sale of these assets. After undergoing a marketing process to solicit interest from potential buyers, and receiving indications of interest from multiple interested parties, HomeStreet, has decided to enter into a non-binding letter of intent with Homebridge to pursue the Transaction. The parties expect to enter into a definitive agreement for a transfer of these assets and related personnel to Homebridge. If the potential Transaction is successful, HomeStreet plans to continue originating home mortgages through its bank locations, online banking services and affinity relationships going forward. HomeStreet will provide additional updates on the sale exploration process at such time as it determines that further disclosure is appropriate or required.

06:09 EDT Culp: GE has 'too much debt,' must reduce it 'thoughtfully and soon' - GE (GE) has too much debt and needs to reduce it "thoughtfully and soon," CEO Lawrence Culp said in a letter to shareholders. "We have more options available to us down the line to generate cash to help bring down our leverage, including our remaining interests in Baker Hughes (BHGE) and Wabtec Corporation (WAB) and continued flexibility for our go-forward Healthcare business," Culp wrote. Culp added that "We intend to maintain a disciplined financial policy, targeting a sustainable credit rating in the single-A range... ultimately a dividend level in line with our peers." "2019 will be a year of change for Power in particular," Culp added. Reference Link

05:55 EDT Microsoft enters collaboration with Telecom Egypt - Microsoft and Telecom Egypt announced their collaboration to extend Microsoft's cloud network to Egypt. Telecom Egypt will provide low-latency connectivity into and across Egypt to help enhance performance and increase reliability for customers of Microsoft services. The partnership will increase Microsoft's reach to the large Egyptian market in addition to improving connectivity across North Africa and the Middle East.

05:35 EDT Adtran to collaborate with IoT.nxt - Adtran announced its collaboration with IoT.nxt to help carriers and enterprises around the world design new services and solutions by bringing together various streams of IoT device data into a single, easy-to-use platform. Based on OpenWrt, the ADTRAN SmartOS Operating System is fully chipset-agnostic, enabling quick and seamless support for any technology or vendor hardware implementation, while also supporting third-party software applications to enhance solution integrations. SmartOS operates on top of five different, leading hardware vendor chipsets and numerous network technologies. With its open data plane and application framework, SmartOS unlocks the potential for streamlined application development and integration of exciting new services. Additionally, the ADTRAN ProCloud suite of subscription-based business services enables enterprises to create improved workflows, based on data collected, and present these in a usable format that can manage devices locally or from the cloud. Combining SmartOS, ProCloud CPaaS and IoT.nxt's leading application, ADTRAN now offers a compelling solution with immediate effect and spanning a virtually unlimited number of both industrial and residential IoT use cases.

05:32 EDT Sabre, Vietnam Airlines sign MOU to expand existing strategic relationship - Vietnam Airlines and Sabre were joined by President of the United States of America Donald Trump, and President of the Socialist Republic of Vietnam, General Secretary of the Communist Party of Vietnam Nguyen Phu Trong, at the Presidential Palace in Hanoi, for the signing of a memorandum of understanding, or MOU, between Sabre and Vietnam Airlines and its subsidiary. The MOU describes Vietnam Airlines' intention to significantly expand their existing strategic relationship with Sabre, with a potential value of over $300M. The scope of the signed MOU includes innovative technology from the Sabre AirVision and AirCenter portfolio, that will complement SabreSonic, Vietnam Airlines' existing Passenger Service System, or PSS, which was recently renewed. Together, Sabre's solutions will help contribute to the carrier's profitability and digital abilities once implemented, supporting their objective to become a digital airline by 2020. Leveraging Sabre's leading Commercial Platform, the MOU contemplates that Sabre's innovative Sabre In-Flight solution would be the first to be adopted by the airline following today's announcement. The solution, which has driven cost savings of up to 10 percent of the total catering budget, would also enhance the airlines' operational efficiency. Additionally, the MOU contemplates a new, long-term domestic content distribution agreement for Vietnam Airlines through the Sabre Global Distribution System.

05:23 EDT Blackstone, Novartis announce launch Anthos Therapeutics - Blackstone Life Sciences (BX) announced the launch of Anthos Therapeutics, a new biopharmaceutical company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients. As part of this launch, Novartis (NVS) has licensed to Anthos MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. A large unmet medical need exists for next-generation anti-thrombotic therapies in patients currently underserved by conventional anti-coagulant therapies. As a promising anti-thrombotic modulating genetically and pharmacologically validated components of the intrinsic pathway, MAA868 has the potential to prevent a variety of cardiovascular disorders with minimal or no bleeding risk within a new long-acting treatment paradigm, which would provide major advantages over the conventional standards of care. Funds managed by Blackstone Life Sciences, a private investment platform with capabilities to invest across the lifecycle of companies and products within the key life sciences sectors, provided $250M for Anthos and will control the development of the products. Novartis will retain a minority equity interest in Anthos. Anthos Therapeutics is based in Cambridge, Massachusetts.

05:15 EDT Nutrien to acquire Ruralco for A$4.40 per share - Nutrien announced that it has entered into a binding agreement with Ruralco Holdings Limited to acquire all the shares of Ruralco at a price of A$4.40 per share. The Nutrien transaction is to be executed via a scheme of arrangement under Australian law and is subject to customary conditions precedent in transactions of this type, including Ruralco shareholder approval and regulatory approval from the Australia Competition and Consumer Commission and the Australian Foreign Investment Review Board. Ruralco has 105,052,247 ordinary shares outstanding and 1,449,648 outstanding performance rights, share rights and matched shares that will vest prior to the record date resulting in a purchase price of A$469M.